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represents good value for money. Using the cost-effectiveness
threshold in Poland (equals to 83,239 PLN/QALY) insulin
glargine should be regarded as a cost-effective option for treat-
ment of patients with type 1 diabetes in Poland.
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OBJECTIVES: Reduced health-related quality of life (HRQoL)
is a pronounced complication in short individuals with Growth
Hormone Deﬁciency (GHD). Treatment options for GHD chil-
dren are limited; however, somatropin therapy has been shown
to normalise height in childhood and adolescence compared
with no treatment. The aim of this study was to establish
whether somatropin is a cost-effective treatment for GHD
children compared with no treatment. METHODS: A cost-
effectiveness model estimated the costs and health beneﬁts over
the lifetime of GHD children. A UK National Health Service
(NHS) perspective was used. Unit costs (GBP; 2008) were
obtained from relevant UK sources. A 3.5% discount rate was
used. Clinical data (height, dosing and treatment duration) were
obtained from a systematic literature review (only studies with
n > 300). Height standard deviation scores (HSDS) were used
for comparable height estimates. Utility data was derived from
a published UK-based study linking HRQOL and HSDS.
Several sensitivity analyses were conducted. RESULTS: Start
HSDS was -2.8 (SD 0.8) and ﬁnal HSDS was -1.5 (SD 0.8)
with somatropin treatment. Untreated children had no HSDS
gain. The mean dose was 0.023 mg/kg/day over 5.1 years dura-
tion (SD 1.8). Over a patient’s lifetime, somatropin was associ-
ated with a gain of 2.0 additional quality adjusted life years
(QALYs) at an incremental cost of £50,931 compared with no
treatment. As a result, somatropin was associated with an incre-
mental cost per QALY of £25,447 compared with no treatment.
Probabilistic sensitivity analysis, in which all parameters within
the model were varied, showed that there was a high probability
that somatropin was cost effective compared with no treatment,
based on a willingness to pay threshold of £30,000 per QALY.
CONCLUSIONS: Based on a willingness to pay threshold
of 30,000 GBP per QALY, somatropin(Norditropin®) is a cost-
effective treatment for GHD children.
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OBJECTIVES: The aim of the study was to evaluate the cost-
utility of Insulin glargine versus premix in insulin naïve and non
insulin naïve patients with type 2 diabetes applied in a Polish
setting. METHODS: Cost-utility analysis from public payer per-
spective was conducted with a 40 years time horizon. The model
used in this evaluation is a DES model which has the ability to
assess the economic impact and health consequences outlined as
the development of co-morbidities of a reduction in hypoglyce-
mia, an improvement in glycaemia or both of these at the same
time. A cohort of 1000 patients was generated in the model.
Hypoglycemia rates and rate reductions were drawn from peer-
reviewed publications. Glycaemia control has been incorporated
into the model using results from The Health Improvement
Network (THIN) database. Polish costs were applied in the
model and only direct medical costs were considered in the
analysis. Sensitivity analysis was performed. RESULTS: When
comparing insulin glargine to premix (using base case results for
background hypoglycemia events) the analyses showed that the
cost per QALY was estimated at 57,678 PLN for insulin naïve
patients and 44,244 PLN for non-insulin naïve patients. The
total estimated discounted costs over a lifetime for insulin naïve
patients were for glargine 23,158,693 PLN and for premix
16,307,845 PLN, total estimated discounted QALYs were for
glargine 6,121 and for premix 6,002. In non-insulin naive
patients costs were for glargine 26,871,051 PLN and for premix
18,813,440 PLN and QALYs were 9,855 and 9,747 for insulin
glargine and premix respectively. CONCLUSIONS: The results
showed that glargine compared to premix represents good value
for money. Using the cost-effectiveness threshold in Poland
(which is equal to 83,239 PLN/QALY) insulin glargine should be
regarded as a cost-effective option for treatment of patients with
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OBJECTIVES: To compare the persistence with insulin Glargine
(BOT = basal supported oral treatment) to those with NPH if
added to oral antidiabetics. METHODS: A retrospective cohort
study was conducted utilizing a representative real-life database
IMS® Disease Analyzer. Patients with type 2 diabetes beginning
insulin therapy with Glargine or NPH during the period 01/2003
to 08/2006 and being continuously eligible for at least 12 months
after the treatment initiation were included. Follow-up was
12–57 months corresponding to the documentation length. Per-
sistence was measured as time until switch to intensiﬁed insulin
therapy (ICT). RESULTS: In total 1,242 patients were included,
of whom 896 were treated with Glargine and 346 with NPH
reﬂecting the distribution in German medical practice. The
patient groups were comparable regarding age and sex and
showed small differences in other characteristics. During
follow-up 13.8% of patients treated with Glargine vs. 20.5%
with NPH (p < 0.001) were switched to ICT. The mean duration
of therapy was 764.1 days on Glargine compared to 654.4 days
on NPH (p < 0.001). In Cox regression analyses beside the type
of insulin patient’s age, diabetes duration and the treating phy-
sician group were signiﬁcantly correlated with the persistence.
No correlation was found for gender, insurance status, region,
type of oral therapy, documentation length and year of insulin
therapy initiation. Adjusting for the factors “age”, “duration of
diabetes” and “physician group” the Cox regression analysis
yielded a hazard ratio of 0.59 (95% CI: 0.40–0.79, p = 0.0005)
for switching to ICT for Glargine compared to NPH. CONCLU-
SIONS: This real-life data analysis showed that patients receiving
BOT with Glargine are treated signiﬁcantly longer compared to
the NPH control group before switching to ICT. Longer treat-
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